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Historically localised aggressive non-Hodgkin’s lymphoma (NHL) has been treated with involved field radiotherapy (RT),
chemotherapy, or a combination of both modalities. The current weight of evidence supports a preference for combined modality
treatment (CMT). Increased patient age at diagnosis is well recognised as a poor prognostic indicator in NHL, but despite this some
perceive CMT as too toxic for use in the elderly. As a result, some older patients continue to be offered RT alone. Here, we present
long-term follow-up of 377 adults of all ages treated with RT alone for early-stage diffuse large-cell lymphoma on British National
Lymphoma Investigation trials between 1974 and 1997. 10-year cause-specific survival in patients older than 60 years was poor and
significantly inferior to that in younger patients (47 and 75% respectively; Po0.001). There is growing evidence that short-course
chemotherapy, with or without RT, is superior to RT alone in early-stage aggressive NHL, in elderly as well as in younger patients.
Increased age alone should not exclude patients from systemic treatment for early-stage aggressive NHL.
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Early stage at diagnosis is a significant predictor of improved
outcome in aggressive non-Hodgkin’s lymphoma (International
Non-Hodgkin’s Lymphoma Prognostic Factors Project, 1993).
Until relatively recently treatment with involved field radiotherapy
(RT) alone, omitting systemic therapy, was an accepted treatment
option in patients with localised disease (Ann Arbor stages I and
II). However, the combination of chemotherapy with RT has now
become more widely used in early-stage disease (Tondini et al,
1993; Glick et al, 1995; Shenkier et al, 2002), and several
investigators have commented that this has coincided with
improvement in survival over the past two decades (Mauch et al,
1985; van der Maazen et al, 1998; Tsang and Gospodarowicz, 2001).
Two randomised comparisons of combined modality therapy
(CMT) against RT alone have confirmed the superiority of CMT
(Monfardini et al, 1980; Nissen et al, 1983). Furthermore, CMT
using RT and short-course chemotherapy improved survival
compared to full-course chemotherapy alone (Miller et al, 1998),
although longer follow-up has demonstrated a convergence of both
failure-free and overall survival (OS) after 8 years (Miller et al,
2000). Recently, the GELA group have demonstrated superior
survival with an intensified chemotherapy regimen alone com-
pared with CMT in low-risk patients (Reyes et al, 2002).
It has been suggested that the toxicity of chemotherapy is
disproportionate to any improvement in outcome in elderly
patients, and that short-course RT alone is an adequate treatment
for this group. There is some evidence that elderly NHL patients
experience more morbidity and mortality from chemotherapy
(Armitage and Potter, 1984), but performance status (PS) rather
than chronological age seems the most significant predictor of
treatment-related death (Gomez et al, 1998). Furthermore, the
elderly may have more to gain from CMT; increased age is an
independent adverse prognostic indicator in aggressive lymphoma
(Sutcliffe et al, 1985; Kaminski et al, 1986; International Non-
Hodgkin’s Lymphoma Prognostic Factors Project, 1993; Vaughan
Hudson et al, 1994; Wylie et al, 1998; Oguchi et al, 2000). There is
evidence that the omission of chemotherapy in this age group
results in poor outcome. 5-year progression-free survival for a
group older than 70 years treated with RT alone was only 31%
(Wylie et al, 1998), compared to 70% in patients over 65 years
given RT plus short-course chemotherapy (Oguchi et al, 1997).
Data for stage I aggressive lymphoma patients from the British
National Lymphoma Investigation (BNLI) have previously shown
10-year disease-free survival (DFS) and OS rates of 45 and 61%,
respectively (Vaughan Hudson et al, 1994), comparable to other
published series (Jones et al, 1973; Chen et al, 1979; Reddy et al,
1989). Here, we present a retrospective analysis of 377 patients
diagnosed with stage IA or IIA diffuse large-cell lymphoma and
registered with the BNLI between 1974 and 1997. All patients were
treated at presentation with RT alone.
PATIENTS AND METHODS
Patients
We have performed a retrospective analysis of 377 adult patients
entered into BNLI studies in the period 1974–1997. In all cases, the
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linitial treatment was involved field RT to a dose of 35–40Gy. The
analysis included only patients with a histological diagnosis of
diffuse large-cell lymphoma carried out at the treating centre.
Central review of histology was performed in all cases. Measure-
ments of serum lactate dehydrogenase (LDH) were not recorded
for the early part of this series and so it was not possible to identify
accurately patients with raised LDH. Performance status data were
not sufficiently complete for analysis. A number of parameters that
were recorded, including ESR, were retrospectively analysed along
with age and stage as a surrogate for the modified International
Prognostic Index (IPI) (Miller et al, 1998). All patients underwent a
bone marrow examination that excluded lymphomatous infiltra-
tion. Primary gut lymphomas were excluded as these may be a
distinct biological entity requiring other treatment modalities
(Isaacson and Wright, 1984; Armitage et al, 2001).
Statistical analysis
Complete response (CR) was defined as the disappearance of all
signs, symptoms and abnormal investigations due to disease for 3
months after completion of initial therapy. Disease-free survival
was measured from the start of treatment to the date of recurrence.
Recurrence was defined as the development of tumour following a
CR to initial treatment. Overall survival included deaths from all
causes, whereas cause-specific survival (CSS) was derived by
censoring deaths not due to lymphoma or its treatment. Survival
was calculated by the life-table method, survival curves were
calculated according to the Kaplan–Meier method (Kaplan and
Meier, 1958) and statistical comparison of curves was performed
using the log-rank test (Peto et al, 1971). Multivariate analysis was
performed using Cox’s proportional-hazards model (Cox, 1972),
the variables included in the analysis being age, stage (Ann-Arbor I
or II), PS, sex, disease site, ESR, haemoglobin concentration and
serum albumin.
RESULTS
Patient characteristics
In all, 424 patients were treated with RT alone for early-stage
diffuse large-cell lymphoma and were registered with the BNLI
during the accrual period. 47 individuals were excluded at
registration because of previous malignancy, incomplete staging
or lack of other baseline data, thus this analysis was confined to the
remaining 377 patients. Median follow-up to date for this group is
12.7 years. There were 202 males and 175 females. Median age was
59 years (range 17–89 years). Patient characteristics are outlined
in Table 1.
Results of treatment
A total of 294 patients (78%) achieved a complete remission. The
complete remission rate for patients aged less than 60 years was
80%, and for older patients 77%. The CR rates for stages I and II
disease were 85 and 58%, respectively. Of those patients achieving
complete remission, 57% remained disease free at 10 years. The
percentage of all treated patients remaining disease free at 10 years
was 44%. The great majority of relapses occurred within the first 5
years following initial treatment. The OS at 10 years was 51%,
rising to 63% when patients dying from causes other than
lymphoma or its treatment were excluded.
Subgroup analysis
Univariate analysis of DFS identified age (X60 years), stage (II vs
I), ESR (X40mmh
 1) and serum albumin (o40gl
 1), but not
haemoglobin, as factors related to inferior DFS. Lactate dehydro-
genase was not recorded for many of the patients in this series.
Multivariate Cox’s regression analysis of DFS identified age
(relative risk (RR) 1.45, 95% confidence interval 1.07–2.00), stage
(RR 2.19, 95% CI 1.57–3.04) and ESR (RR 2.15, 95% CI 1.30–3.55)
as significant risk factors related to relapse. The DFS at 10 years for
the patients aged 60 years and over was 35%, compared to 52% for
the younger group. The percentage of patients in each stage and
age group remaining disease free following initial RT is shown in
Figures 1 and 2.
Age, stage, ESR and serum albumin were also identified as risk
factors related to CSS. Disease site (nodal vs extranodal) did not
predict survival in this series. Age (RR 2.92, 95% CI 1.94–4.39),
stage (RR 1.71, 95% CI 1.11–2.65) and serum albumin (RR 1.55,
Table 1 Patient characteristics
No. of patients 377
Median age (range) (years) 59 (17–89)
Sex ratio (male:female) 1.15:1
Stage IA 292 (77%)
Stage IIA 85 (23%)
Disease site
Nodal disease only 189 (50%)
Extranodal only 136 (36%)
Nodal and extranodal 49 (13%)
Unknown 3 (1%)
5 1 01 52 02 53 0
20
40
60
80
100
Years
%
 
d
i
s
e
a
s
e
 
f
r
e
e
P < 0.0001
Stage I (n = 292)
Stage II (n = 85)
Figure 1 Percentage of patients with early aggressive NHL remaining
disease free after initial RT according to stage.
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Figure 2 Percentage of patients with early aggressive NHL remaining
disease free after initial RT according to age.
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l95% CI 1.01–2.39) remained significant following multivariate
analysis. The survival curves for patients in each stage and
age group are shown in Figures 3 and 4. The CSS at 10 years for the
patients aged 60 years and over was 47%, compared to 75% for the
younger group. Combining age and stage information divides
the cohort into groups with widely divergent outcomes; CSS at 10
years in young stage I patients was 79%, compared to only 31% in
older patients with stage II disease (Figure 5). The importance of
advanced age as a risk factor is emphasised by the inferior long-
term survival of older patients with stage I disease even compared
to those with more advanced (stage II) disease in the younger group.
DISCUSSION
The overall CR rate of 78%, and 10 year DFS, OS and CSS rates of
44, 51 and 63%, respectively, are comparable with those achieved
by other groups treating early NHL with RT alone (Timothy et al,
1980; Hagberg et al, 1989). Failure to achieve CR was generally due
to the appearance of disease elsewhere, not detected at staging,
within 3 months of treatment, rather than a result of radiation
resistance. Multivariate analysis reveals groups of patients with
significantly poorer prognosis. Increased age and stage are
recognised as adverse components of the IPI in NHL (International
Non-Hodgkin’s Lymphoma Prognostic Factors Project, 1993), and
old age was included in the modified IPI applied to early-stage
NHL (Miller et al, 1998). Elderly and younger patients in this BNLI
series enjoyed similar response rates following treatment with RT
alone; however, in the elderly survival was significantly inferior.
CSS at 10 years was 47% in patients older than 60 years compared
with 75% for younger patients. 10-year DFS was similarly poor in
the elderly (35% for patients older than 60 years and 52% for those
younger). The similarity between DFS and CSS in this group is
indicative of the failure of salvage therapy to produce meaningful
survival benefit, although details of salvage treatment are not
available.
This analysis includes 38 patients treated before 1980 and 255
treated before 1990. Disease-free survival, but not OS or CSS, was
significantly superior in patients treated more recently (not
shown). However, differences between DFS, OS and CSS for the
two age groups remained highly significant when only those
patients treated since 1990 were analysed (P¼0.004, o0.001 and
o0.001, respectively). This suggests that the inferior results for
older patients reported here do not merely reflect obsolete
standards of diagnosis, treatment or supportive care.
In addition to age and stage, multivariate analysis found ESR to
be an adverse predictor of DFS. Like LDH, which was not recorded
in the earlier years of this series, ESR is likely to serve as a
surrogate for disease activity. Similarly, albumin is an independent
predictor of CSS. Like ESR, albumin may correlate with disease
activity, but may also integrate a measure of comorbidity, which
was not itself recorded but is likely to be a predictor of poor
outcome in older patients.
The poor outcome in elderly patients treated with RT alone
suggests that this group should also be offered systemic therapy.
The perception that the elderly respond to and tolerate
chemotherapy poorly is not necessarily supported by the evidence
(Jones et al, 1989), and short-course chemotherapy was originally
specifically designed for the elderly (O’Reilly et al, 1990).
Algorithms have been developed that allow the identification of
elderly patients who are more or less functionally impaired by the
ageing process (Saliba et al, 2001). This method may be used to
select patients for treatment according to their true fitness rather
than by chronological age alone. Nevertheless, ageing is associated
with reduced functional reserve in many organ systems including
bone marrow (Chatta and Dale, 1996). This has been perceived as a
major barrier to systemic chemotherapy in the elderly because
myelosuppression is the most frequent dose-limiting toxicity of
such treatment. However, recombinant growth factors are now
widely available and are effective in many tumour types including
aggressive NHL (Pettengell et al, 1992; Zinzani et al, 1997). The
benefits of growth factors extend to the elderly despite their
depleted reserve (Balducci and Lyman, 2001).
A recent comparison of short-course CHOP chemotherapy with
or without involved field RT in elderly patients with localised
disease showed equivalent overall and CSS in the two groups (Fillet
et al, 2002). This implies that the addition of RT to short-course
chemotherapy provides no additional benefit. Indeed, the addition
of RT may be detrimental in the oldest patients as subgroup
analysis showed superior OS following chemotherapy alone in
those over 69 years (Fillet et al, 2002).
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Figure 3 Cause-specific survival according to stage of patients with early
aggressive NHL.
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Figure 4 Cause-specific survival according to age of patients with early
aggressive NHL.
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Figure 5 Cause-specific survival according to age and stage of patients
with early aggressive NHL.
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lThe poor outcome reported here for older patients treated with
RT alone, even when selected for early stage, indicates that
chemotherapy should not be omitted in the elderly for the reason
that their age in itself predicts poor outcome. Thus fit older
patients with early-stage lymphoma should be offered CMT or
even chemotherapy alone.
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